David A. Siegel Arrowhead Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 100,000 shares of ARWR stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,000
Previous 102,100
2.06%
Holding current value
$1.87 Million
Previous $2.65 Million
27.03%
% of portfolio
0.0%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding ARWR
# of Institutions
295Shares Held
91.1MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$293 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$229 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$166 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$119 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.89MShares$91.4 Million1.49% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $1.98B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...